Panaxia Pharmaceuticals Industries is set on transforming pharmaceutical cannabis by bringing to the game consistent, effective, and high-quality cannabis products. An Israeli company, Panaxia Pharmaceuticals Industries develops cannabis products that are conventional to drug delivery such as tablets and suppositories, since many chronic patients cannot smoke or vape. 

Just this week, Panaxia Pharmaceuticals Industries had a patent application (US Pub. No. 20200146984) published for a cannabinoid composition having enhanced therapeutic potency. Enhanced potency is achieved by the addition of either an essential oil, with the following explicitly mentioned - cinnamomum leaf, salvia sclarea, canarium luzonicum, or Origanum vulgare - or a herbal extract, with the following explicitly mentioned - silybum marianum, cranberry, or clove - or a sleep-aid, with the following explicitly mentioned -  doxylamine, diphenhydramine, or melatonin. The enhanced potency cannabinoid composition is in gel form for treating conditions modulated by the CB1 and CB2 receptors of the endocannabinoid system, especially sleep disorders. 

Are you directly involved in cannabis processing and looking to further develop your technology and establish valuable IP assets? Magic Number’s Cannabis Patent Forecast® can assist companies explore competitive intelligence to find uncontested markets and areas waiting to be tapped-into. Visit Magic Number for more information.